MX2016001195A - Metodos para mejorar sintomas de asma mediante el uso de benralizumab. - Google Patents
Metodos para mejorar sintomas de asma mediante el uso de benralizumab.Info
- Publication number
- MX2016001195A MX2016001195A MX2016001195A MX2016001195A MX2016001195A MX 2016001195 A MX2016001195 A MX 2016001195A MX 2016001195 A MX2016001195 A MX 2016001195A MX 2016001195 A MX2016001195 A MX 2016001195A MX 2016001195 A MX2016001195 A MX 2016001195A
- Authority
- MX
- Mexico
- Prior art keywords
- benralizumab
- methods
- asthma symptoms
- improving asthma
- improving
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Se presentan los métodos para mejorar los síntomas de asma, por ejemplo, conforme se miden en un cuestionario de control de asma, que comprende administrar al paciente una cantidad efectiva de benralizumab o un fragmento de unión al antígeno de este.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361864950P | 2013-08-12 | 2013-08-12 | |
PCT/US2014/050122 WO2015023508A2 (en) | 2013-08-12 | 2014-08-07 | Methods for improving asthma symptoms using benralizumab |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016001195A true MX2016001195A (es) | 2016-07-21 |
MX368474B MX368474B (es) | 2019-10-04 |
Family
ID=52448839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016001195A MX368474B (es) | 2013-08-12 | 2014-08-07 | Uso de benralizumab para mejorar síntomas de asma. |
Country Status (18)
Country | Link |
---|---|
US (1) | US9441047B2 (es) |
EP (3) | EP3536339B1 (es) |
JP (2) | JP6803229B2 (es) |
KR (1) | KR102337601B1 (es) |
CN (2) | CN111617244A (es) |
AU (3) | AU2014306960B2 (es) |
BR (1) | BR112016002462A8 (es) |
CA (1) | CA2918050C (es) |
DK (2) | DK3033103T3 (es) |
ES (2) | ES2901634T3 (es) |
HK (2) | HK1221647A1 (es) |
HU (2) | HUE057065T2 (es) |
MX (1) | MX368474B (es) |
PL (2) | PL3033103T3 (es) |
RU (2) | RU2020123894A (es) |
SG (1) | SG11201600484TA (es) |
TR (1) | TR201910413T4 (es) |
WO (1) | WO2015023508A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111588848A (zh) * | 2013-08-12 | 2020-08-28 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗降低哮喘恶化率的方法 |
PL3033104T3 (pl) * | 2013-08-12 | 2019-09-30 | Astrazeneca Ab | Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu |
EP3057609A4 (en) * | 2013-10-15 | 2017-03-22 | Medlmmune, LLC | Methods for treating chronic obstructive pulmonary disease using benralizumab |
EP3371225A2 (en) | 2015-11-04 | 2018-09-12 | AstraZeneca AB | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69633973T2 (de) | 1995-09-11 | 2005-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
AU2001232304A1 (en) | 2000-02-15 | 2001-08-27 | Kyowa Hakko Kogyo Co. Ltd. | Eosinophil-specific apoptosis inducer |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
AU2004279740A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
CA2986531C (en) * | 2007-05-14 | 2020-02-25 | Astrazeneca Ab | Methods of reducing eosinophil levels |
EP2652498B1 (en) * | 2010-12-16 | 2018-04-18 | F.Hoffmann-La Roche Ag | Diagnosis and treatments relating to th2 inhibition |
US8961965B2 (en) * | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
WO2013066780A2 (en) | 2011-11-01 | 2013-05-10 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
CN111588848A (zh) * | 2013-08-12 | 2020-08-28 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗降低哮喘恶化率的方法 |
PL3033104T3 (pl) * | 2013-08-12 | 2019-09-30 | Astrazeneca Ab | Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu |
-
2014
- 2014-08-07 US US14/454,149 patent/US9441047B2/en active Active
- 2014-08-07 PL PL14836392T patent/PL3033103T3/pl unknown
- 2014-08-07 HU HUE19162585A patent/HUE057065T2/hu unknown
- 2014-08-07 EP EP19162585.4A patent/EP3536339B1/en active Active
- 2014-08-07 CN CN202010449449.1A patent/CN111617244A/zh active Pending
- 2014-08-07 MX MX2016001195A patent/MX368474B/es active IP Right Grant
- 2014-08-07 ES ES19162585T patent/ES2901634T3/es active Active
- 2014-08-07 PL PL19162585T patent/PL3536339T3/pl unknown
- 2014-08-07 WO PCT/US2014/050122 patent/WO2015023508A2/en active Application Filing
- 2014-08-07 CN CN201480044052.7A patent/CN105451761A/zh active Pending
- 2014-08-07 AU AU2014306960A patent/AU2014306960B2/en active Active
- 2014-08-07 RU RU2020123894A patent/RU2020123894A/ru unknown
- 2014-08-07 ES ES14836392T patent/ES2740355T3/es active Active
- 2014-08-07 DK DK14836392.2T patent/DK3033103T3/da active
- 2014-08-07 HU HUE14836392A patent/HUE045402T2/hu unknown
- 2014-08-07 RU RU2016108734A patent/RU2728578C2/ru active
- 2014-08-07 BR BR112016002462A patent/BR112016002462A8/pt not_active Application Discontinuation
- 2014-08-07 EP EP14836392.2A patent/EP3033103B1/en active Active
- 2014-08-07 DK DK19162585.4T patent/DK3536339T3/da active
- 2014-08-07 EP EP21188229.5A patent/EP3988114A1/en not_active Withdrawn
- 2014-08-07 TR TR2019/10413T patent/TR201910413T4/tr unknown
- 2014-08-07 KR KR1020167006565A patent/KR102337601B1/ko active IP Right Grant
- 2014-08-07 JP JP2016534616A patent/JP6803229B2/ja active Active
- 2014-08-07 CA CA2918050A patent/CA2918050C/en active Active
- 2014-08-07 SG SG11201600484TA patent/SG11201600484TA/en unknown
-
2016
- 2016-08-16 HK HK16109789.8A patent/HK1221647A1/zh unknown
- 2016-12-01 HK HK16113685A patent/HK1225303A1/zh unknown
-
2020
- 2020-02-28 JP JP2020032499A patent/JP2020100653A/ja not_active Withdrawn
- 2020-04-16 AU AU2020202564A patent/AU2020202564A1/en not_active Abandoned
-
2023
- 2023-08-10 AU AU2023214323A patent/AU2023214323A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
MX370818B (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
MY157341A (en) | Methods and compositions for treating lung cancer | |
AU2014306956B2 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX2015006337A (es) | Metodos y composiciones para tratar enfermedades neurodegenerativas. | |
MX2021003826A (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
EA201491581A1 (ru) | Везикулярные композиции | |
CL2017002304A1 (es) | Métodos para tratar enfermedades | |
EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
TN2013000114A1 (en) | Methods and compositions for treating lung cancer | |
TR201106224A2 (tr) | Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler. | |
TH127247B (th) | องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง | |
UA112965C2 (uk) | Гуманізоване антитіло до il-25 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: ASTRAZENECA AB |
|
FG | Grant or registration |